Noradrenalină Kalceks (Norepinephrine)

Norepinephrine activates alpha‑1 adrenergic receptors, causing strong vasoconstriction and raising systemic vascular resistance. It also stimulates beta‑1 receptors, modestly increasing heart rate and contractility, together improving arterial pressure and organ perfusion.

The dosage of Noradrenalină Kalceks is individualized. A qualified prescriber determines the infusion rate based on the patient’s blood pressure, cardiac output, and clinical response, and then titrates the dose to achieve target hemodynamics.

Safety data for norepinephrine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Norepinephrine is generally preferred over dopamine because it provides more predictable vasoconstriction with fewer arrhythmic effects. Compared with phenylephrine, norepinephrine also offers modest beta‑1 activity, supporting cardiac output while raising blood pressure.

The product must be stored refrigerated at 2‑8 °C, protected from light, and never frozen. Before use, allow the solution to reach room temperature if required, and avoid shaking the vial to maintain solution integrity.

Noradrenalină Kalceks is given by continuous intravenous infusion. The infusion is started at a low rate and titrated upward while monitoring blood pressure and heart rate, using a calibrated infusion pump for precise control.

Serious risks include severe hypertension, myocardial ischemia, tissue necrosis at the infusion site, and, in rare cases, pulmonary edema or cardiac arrest. Continuous hemodynamic monitoring is essential to detect these complications early.

Contraindications include patients with known pheochromocytoma, uncorrected hypovolemia, or severe peripheral vascular disease where vasoconstriction could cause tissue loss. Caution is also advised in patients with recent myocardial infarction or uncontrolled arrhythmias.